

Use of Bortezomib (Velcade®) within NHS Wales

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA129)

NICE GUIDANCE ISSUED OCTOBER 2007

(Refer to NICE website for full guidance on NICE recommendations,
including any specific restrictions on the use of the technology)

Please disseminate the following information to the appropriate individuals within your organisation across NHS Wales.

Dear Colleague

The Minister for Health & Social Services has endorsed AWMSG's recommendation that:

The use of bortezomib (Velcade®) should be supported within NHS Wales in accordance with its licensed indications for the treatment of multiple myeloma for patients who have received two prior treatments and have demonstrated disease progression. Treatment must only be initiated and administered under the supervision of a physician qualified and experienced both in the use of chemotherapeutic agents and in the management of multiple myeloma.

If you wish to view the appraisal meeting documentation please click on the link below.

<http://www.wales.nhs.uk/sites3/page.cfm?orgid=371&pid=7068>

This information has been disseminated by the AWMSG Secretariat.

Professor Roger Walker
Chairman AWMSG

12 August 2005

Enquiries: please contact

Mrs Ruth Lang
Liaison Manager
Welsh Medicines Partnership
Dept Pharmacology, Therapeutics & Toxicology
Cardiff University
Wales College of Medicine
Heath Park, Cardiff, CF14 4XN

Tel: 029 20745466

Website address: www.wales.nhs.uk/awmsg/